Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Adenosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 known ✓ | P0DMS8 | 4/20 | 0.97 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 0.97 |
| ▸ | ADORA2B known ✓ | P29275 | 1/20 | 0.97 |
| ▸ | ADORA1 known ✓ | P30542 | 1/20 | 0.97 |
| ▸ | DPP4 | P27487 | 1/20 | 0.97 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.97 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.97 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.97 |
| ▸ | GAPDH | P04406 | 1/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.97 |
| ▸ | STAT6 | P42226 | 1/20 | 0.97 |
| ▸ | PI4KA | P42356 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.97 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.97 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.97 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.97 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.97 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vidarabine SCHEMBL30994790 | 1.00 | ADORA3 (0.97) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Vidarabine SCHEMBL15741481 | 1.00 | ADORA3 (0.97) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Vidarabine SCHEMBL1046366 | 1.00 | ADORA3 (0.97) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL5500833 | 1.00 | ADORA3 (0.97) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Vidarabine SCHEMBL2929 | 1.00 | ADORA3 (0.97) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Vidarabine SCHEMBL4993136 | 1.00 | ADORA3 (0.97) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL10764695 | 1.00 | ADORA3 (0.97) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL4280020 | 1.00 | ADORA3 (0.97) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL5078118 | 1.00 | ADORA3 (0.97) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL27624165 | 1.00 | ADORA3 (0.97) | ADORA3DPP4MEN1SLC28A1MAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110470754-A | A kind of method of cordycepin content in high effective liquid chromatography for measuring cordyceps sinensis | UNIV WUHAN | 2019-11-19 | — | — | CN | claimed |
| CN-110201156-A | Predictability biomarker use for cancer treatment | 莫洛根股份公司 | 2019-09-06 | — | — | CN | claimed |
| CN-105247365-B | Predictive biomarkers for cancer treatment | 莫洛根股份公司 | 2019-06-18 | — | — | CN | claimed |
| CN-109890808-A | Therapeutic compounds for prophylactic or therapeutic treatment of HIV viral infections | 吉利德科学公司 | 2019-06-14 | — | — | CN | claimed |
| CN-108008128-A | Aptamer identifies and the kanamycins quick detection test paper of functionalized magnetic microsphere separation and culture and its preparation and application | 江南大学 | 2018-05-08 | — | — | CN | claimed |
| CN-107206087-A | Specific MTOR inhibitors in the treatment of X-linked adrenoleukodystrophy | 瓦伦西亚普林西比菲利普中心团体投资基金会 | 2017-09-26 | — | — | CN | claimed |
| CN-101680039-B | Enzyme anti-cancer treatment | 希格马托罕见疾病有限公司 | 2016-08-24 | — | — | CN | claimed |
| US-11584773-B2 | Phosphorous protecting groups and methods of preparation and use thereof | AGILENT TECHNOLOGIES, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| EP-3943500-A1 | PHOSPHOROUS PROTECTING GROUPS AND METHODS OF PREPARATION AND USE THEREOF | Agilent Technologies, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| US-20220002334-A1 | PHOSPHOROUS PROTECTING GROUPS AND METHODS OF PREPARATION AND USE THEREOF | UNIVERSITY OF COLORADO BOULDER | 2022-01-06 | — | — | US | disclosed |
| EP-3137478-B1 | PHOSPHOROUS PROTECTING GROUPS AND METHODS OF PREPARATION AND USE THEREOF | AGILENT TECHNOLOGIES INC (US) | 2021-09-22 | — | — | EP | disclosed |
| CN-112584847-A | Behavior therapy | 默多克儿童研究所 | 2021-03-30 | — | — | CN | disclosed |
| CN-106255697-B | Phosphorus protecting group and preparation method and application thereof | 安捷伦科技有限公司 | 2020-04-28 | — | — | CN | disclosed |
| CN-104998264-A | Method and composition for treating mammalian diseases and injuries caused by the over-expression of peroxynitrite | North Cell Pharmacetical | 2015-10-28 | — | — | CN | disclosed |
| WO-2013026424-A1 | A METHOD FOR THE PREPARATION OF 2-[4-[(METHYLAMINO) CARBONYL] -1-H-PYRAZOL-1-YL] ADENOSINE MONOHYDRATE | FARMAK, A.S. (CZ) | 2013-02-28 | — | — | WO | disclosed |
| WO-2013026424-A1 | A METHOD FOR THE PREPARATION OF 2-[4-[(METHYLAMINO) CARBONYL] -1-H-PYRAZOL-1-YL] ADENOSINE MONOHYDRATE | FARMAK, A.S. (CZ) | 2013-02-28 | — | — | WO | disclosed |
| CN-101820753-A | Methods of treating pulmonary disease states in mammals by up-or down-regulating indigenous in-vivo levels of inflammatory mediators in mammalian cells | CELLULAR SCIENCES INC | 2010-09-01 | — | — | CN | disclosed |
| CN-101687900-A | Double-stranded locked nucleic acid compositions | NVENTA BIOPHARMACEUTICALS CORP | 2010-03-31 | — | — | CN | disclosed |
| CN-101443357-A | MCP1 fusion | SCHERING CORP (US) | 2009-05-27 | — | — | CN | disclosed |
| CN-101115505-A | Methods and compositions for treating mammalian diseases and wounds caused by peroxynitrite overexpression | NORTH CELL PHARMACEUTICAL INC (US) | 2008-01-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002334-A1 | PHOSPHOROUS PROTECTING GROUPS AND METHODS OF PREPARATION AND USE THEREOF | POLN, POLRMT, NUDT21 | ADORA3 1735/4885ADORA2A 1586/4885ADORA2B 1593/4885 |
| US-11584773-B2 | Phosphorous protecting groups and methods of preparation and use thereof | POLN, POLRMT, NUDT21 | ADORA3 1735/4885ADORA2A 1586/4885ADORA2B 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.